AbbVie | ABBV - Equity Capital And Reserves



AbbVie reported $1.46B in Equity Capital and Reserves for its fiscal quarter ending in March of 2025.


Equity Capital And Reserves Change Date
AbbVie USD 1.46B 1.86B Mar/2025
Abbott USD 50.83B 1.76B Jun/2025
ALKERMES USD 1.62B 113M Jun/2025
Amgen USD 7.43B 1.22B Jun/2025
AstraZeneca USD 44.72B 3.68B Jun/2025
Biogen USD 17.63B 655.3M Jun/2025
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Eisai JPY 828.51B 12.91B Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
Gilead Sciences USD 19.67B 596M Jun/2025
GlaxoSmithKline GBP 14.35B 197M Jun/2025
J&J USD 78.11B 6.62B Mar/2025
Medtronic USD 48.02B 1.36B Apr/2025
Merck USD 49.06B 725M Jun/2025
Neurocrine Biosciences USD 2.69B 158.6M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Pacira USD 757.77M 40.77M Jun/2025
Perrigo USD 4.47B 108.3M Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Regeneron Pharmaceuticals USD 29.94B 551.3M Jun/2025
Roche Holding CHF 36.16B 3.28B Dec/2024
Sanofi 70.28B 3.8B Jun/2025
UCB EUR 10.03B 1.08B Dec/2024
Ultragenyx Pharmaceutical USD 151.29M 7.04M Jun/2025
United Therapeutics USD 7.17B 366.4M Jun/2025
Vertex Pharmaceuticals USD 17.18B 679.1M Jun/2025
Zoetis USD 4.98B 322M Jun/2025